Virtual Library
Start Your Search
D. Zheng
Author of
-
+
P2.05 - Poster Session with Presenters Present (ID 463)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.05-028 - Comparison of Adjuvant Chemotherapy with or without Radiotherapy in NSCLC Patients with Stage IIIA-Single Station N2 (ID 4165)
14:30 - 14:30 | Author(s): D. Zheng
- Abstract
Background:
The role of adjuvant radiotherapy (ART) on stage IIIA-N2 NSCLC is still controversial especially in different status of lymph nodes invasion. We conducted this retrospective study here to evaluate the effect of adjuvant radiotherapy (ART) on non-small cell lung cancer (NSCLC) patients with resectable stage IIIA--single station N2.
Methods:
Between January 2010 and December 2013, 383 resectable NSCLC patients with stage IIIA-single station N2 were recruited in Shanghai Pulmonary Hospital. The patients received neoadjuvant therapy or no adjuvant chemotherapy (ACT) and those were mixed with small cell lung cancer components were excluded from the study. Their clinicopathological data were collected and their survival times were recorded. The last follow-up was finished on May 31, 2016. Kaplan-Meier survival method was used here to calculate the overall survival (OS) , disease-free survival (DFS) and Cox regression analysis was used to conduct multivariate analysis.
Results:
Overall 341 patients with median age of 59 yrs (25-79yrs) were included. There were 164 patients with adenocarcinoma (AD), 106 with squamous cell lung cancer (SCC) and 61 others (37 with adenosquamous, 26 with large cell carcinoma and 8 with sarcomatoid carcinoma). Totally 26 patients were lost of follow-up. One hundred and eighty-nine patients (55.4%) were confirmed recurrence and 152 patients (44.6%) died until the last follow-up. Among them, 79 patients received ART and ACT after operation and 262 patients only completed ACT. The patients’ baseline characteristics of these two groups were balanced. The median DFS for the whole group patients, ART+ACT group and ACT group were 30 (23.9-36.1), 31 (19.8-42.2) and 30 (21.8-34.2) months respectively. The median OS for the whole group patients, ART+ACT group and ACT group were 52 (39.4-64.6), 54 (NR) and 50(36.7-63.3) months respectively. Multivariate analysis showed no difference in DFS and OS between ART+ACT and ACT groups. In subgroup analysis, we found the significant benefit in favor of ART (n=44) regarding DFS (HR 0.55 , 95% CI 0.323-0.938, p =0.028), and a tendency in OS (HR 0.553, 95% CI 0.284-1.078, p =0.082) in AD patients. While in SCC patients, ART (n=18) seemed a poor prognostic factor. (HR 2.0 for DFS, 95% CI 0.935-2.485, p = 0.074 and HR 0.757 for OS, 95% CI 0.225-2.553, p =0.654).
Conclusion:
ART significantly decreased the risk of recurrence in Adenocarcinoma patients with stage IIIA-single station N2 and might improve these patients’ survival. The benefit of ART for SCC patients didn’t be proved here.
